Press

Notice of Annual General Meeting in Acarix AB

 

April 16, 2019

The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on Thursday 16 May 2019, at 10.00 at Baker & McKenzie Advokatbyrå's premises at Vasagatan 7 in Stockholm.

Notice to Annual General meeting

Nomination committee's full proposal and motivated opinion

Proxy form

For further information, please contact:
Per Persson, CEO
E-mail: per.persson@acarix.com
Phone: +46 73 600 59 90

Acarix is listed on Nasdaq First North in Stockholm. Wildeco Ekonomisk Information AB (+46 8 545 281 00, info@wildeco.se) is Certified Adviser to Acarix

About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.